Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 2Suspended 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 1131Neoplasms 986Carcinoma, Non-Small-Cell Lung 903Prostatic Neoplasms 595Neoplasm Metastasis 529Leukemia, Myeloid, Acute 514Colorectal Neoplasms 492Lung Neoplasms 490Melanoma 488Multiple Myeloma 478Pancreatic Neoplasms 387Lymphoma 370Ovarian Neoplasms 368Recurrence 365Lymphoma, Non-Hodgkin 348Leukemia 340Leukemia, Lymphocytic, Chronic, B-Cell 322Precursor Cell Lymphoblastic Leukemia-Lymphoma 291Head and Neck Neoplasms 276Carcinoma, Renal Cell 276Brain Neoplasms 276Carcinoma, Hepatocellular 261Glioblastoma 250Myelodysplastic Syndromes 244Lymphoma, Large B-Cell, Diffuse 244Squamous Cell Carcinoma of Head and Neck 241Lymphoma, Follicular 236Colonic Neoplasms 214Stomach Neoplasms 200Rectal Neoplasms 190

Interventions

Natalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Multiple Sclerosis, Chronic Progressive × Clear all
NCT03283826 2024-02-23

EMBOLD

Atara Biotherapeutics

Phase 1/2 Terminated
134 enrolled

Autoimmune Diseases, Demyelinating Diseases, Inflammation, Multiple Sclerosis, Epstein-Barr Virus Infections, Multiple Sclerosis, Chronic Progressive

NCT01416181 2017-09-11

ASCEND in SPMS

Biogen

Phase 3 Terminated
889 enrolled 31 charts

Multiple Sclerosis, Neoplasm Metastasis, Multiple Sclerosis, Chronic Progressive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡